Biogen To Spend $75M For Fibrosis Drug Co. Stromedix
Coming off a year in which its earnings topped $5 billion, drugmaker Biogen Idec Inc. has struck a deal to pay $75 million — and possibly much more — for privately...To view the full article, register now.
Already a subscriber? Click here to view full article